Ponatinib-Blinatumomab Outperforms Imatinib-Chemotherapy in Ph-Positive ALL

A phase 3 trial randomized adult patients with Philadelphia-positive acute lymphoblastic leukemia to frontline ponatinib plus blinatumomab versus imatinib plus chemotherapy. The trial reported higher 24-month event-free survival (86% vs 67%), higher rates of molecular response after consolidation, and lower cumulative relapse incidence (5% vs 13%) with the ponatinib-blinatumomab regimen; overall survival was 90% versus 85%. The trial noted that only 19% of patients in the intervention group underwent stem-cell transplantation after first complete hematologic response.

Most relevant for: Adult patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia being considered for frontline treatment.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.